tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Venz S et al. Contribution of color and power Doppler sonography to the differential diagnosis of acute and chronic rejection, and tacrolimus nephrotoxicity in renal allografts. 1999 Transpl. Int. pmid:10363595
Onsager DR et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. 1999 J. Heart Lung Transplant. pmid:10363689
Ito F et al. FK506 and cyclosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9. 1999 Arch. Dermatol. Res. pmid:10367710
Przepiorka D et al. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. 1999 Biol. Blood Marrow Transplant. pmid:10371361
Matzinger P Graft tolerance: a duel of two signals. 1999 Nat. Med. pmid:10371494
Kirk AD et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. 1999 Nat. Med. pmid:10371508
Lieberman DN and Mody I Properties of single NMDA receptor channels in human dentate gyrus granule cells. 1999 J. Physiol. (Lond.) pmid:10373689
Cox KL et al. Paediatric liver transplantation: indications, timing and medical complications. 1999 J. Gastroenterol. Hepatol. pmid:10382641
Higgins RM et al. Conversion between cyclosporin and tacrolimus--30-fold dose prediction. 1999 Nephrol. Dial. Transplant. pmid:10383044
Henry ML Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. 1999 Clin Transplant pmid:10383101
Koski GK et al. Calcium mobilization in human myeloid cells results in acquisition of individual dendritic cell-like characteristics through discrete signaling pathways. 1999 J. Immunol. pmid:10384103
Leung W et al. Long-term complete remission and immune tolerance after intensive chemotherapy for lymphoproliferative disorders complicating liver transplant. 1999 Transplantation pmid:10385092
Squadrito F et al. Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock. 1999 Br. J. Pharmacol. pmid:10385251
Gerhardt U et al. Blood pressure control in kidney transplant recipients: influence of immunosuppression. 1999 J Auton Pharmacol pmid:10385269
Liang H et al. Regulation of angiotensin II-induced phosphorylation of STAT3 in vascular smooth muscle cells. 1999 J. Biol. Chem. pmid:10391929
Hasselder AS The nursing management of a patient receiving Prograf as a primary immunosuppressive agent. 1998 Apr-Jun EDTNA ERCA J pmid:10392057
Horowitz MM et al. Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. 1999 Biol. Blood Marrow Transplant. pmid:10392964
Kochi S et al. Effect of cyclosporin A or tacrolimus on the function of blood-brain barrier cells. 1999 Eur. J. Pharmacol. pmid:10395024
Magee CC et al. Immunosuppressive agents in organ transplantation. 1999 Hosp Med pmid:10396414
Gold BG et al. Efficacy of delayed or discontinuous FK506 administrations on nerve regeneration in the rat sciatic nerve crush model: lack of evidence for a conditioning lesion-like effect. 1999 Neurosci. Lett. pmid:10400242